Retatrutide Side Effects

Answer first: the side effects reported for retatrutide in its phase-2 obesity trial were overwhelmingly gastrointestinal — nausea, diarrhoea, vomiting, constipation and decreased appetite. In that trial these events were dose-related, mostly mild to moderate, appeared mainly during dose escalation, and were partly reduced by starting at a lower dose. A dose-dependent rise in resting heart rate was also observed. The decisive caveat is that this picture comes from a single, small, 48-week study: retatrutide is investigational and not an approved medicine, so its safety evidence base is far smaller and earlier than semaglutide's or tirzepatide's, and no long-term human safety data exists. This page summarises what the phase-2 trial reported, framed for research reference only.

Retatrutide is a triple-hormone-receptor agonist — one molecule acting on the GIP, GLP-1 and glucagon receptors — studied in the phase-2 trial published by Jastreboff and colleagues in 2023. BeSkinny stocks it as a research-grade compound in the retatrutide range. Everything below describes what that early trial observed; none is medical, prescribing or dosing advice, and none is reassurance that the compound is well characterised.

The short version

• The dominant reported effects were gastrointestinal and mostly mild to moderate in the trial.
• They were dose-related and clustered during escalation, rising with higher doses.
• A lower starting dose (2 mg rather than 4 mg) partly reduced the gastrointestinal events.
• Resting heart rate rose in a dose-dependent way through about 24 weeks, then declined.
• The evidence is early and thin: one phase-2 study, roughly 338 people, 48 weeks, no long-term data — treat every figure as preliminary.

Side effects: what the phase-2 trial reported

The table groups the effects the phase-2 trial recorded. The figures are trial observations across the dose groups, not an outcome you should expect from any research protocol, and they come from a single small study rather than the large label datasets that back the approved compounds.

Category	What the phase-2 trial reported
Common (the leading reported events)	Gastrointestinal effects dominated: nausea, diarrhoea, vomiting, constipation and decreased appetite. They were dose-related and mostly mild to moderate. Nausea was the most frequent and rose sharply with dose — from roughly 14% of participants at the lowest 1 mg dose to around 60% at the top 12 mg dose. Diarrhoea, vomiting and constipation were less frequent but followed the same upward, dose-dependent pattern, and appeared mainly during the escalation phase.
Less common	A dose-dependent increase in resting heart rate, which rose through about 24 weeks and then declined over the weeks that followed; injection-site reactions and headache were also reported. Decreased appetite is an expected pharmacological effect of the mechanism rather than an incidental one.
Serious or monitored	Serious adverse events were uncommon — 0% to about 6% across the retatrutide dose groups, against roughly 4% on placebo. Adverse events led 6% (1 mg) to 16% (12 mg) of participants to stop, mostly during escalation rather than maintenance, and the heart-rate rise was the main signal formally monitored. Crucially, a 48-week trial this size cannot rule out the rarer serious effects recognised across the incretin class (such as pancreatitis or gallbladder disease seen with approved GLP-1 medicines); their absence here reflects the small, short evidence base, not established safety.

Across the trial, overall adverse events were reported by about 70% of the placebo group and roughly 73% to 94% of the retatrutide groups, highest at the 8 mg and 12 mg doses. The consistent message: gastrointestinal events led, were dose-related, were mostly mild to moderate, and clustered in the weeks when the dose was being raised.

Evidence maturity: why this matters most

The single most important thing about retatrutide's side-effect profile is how little evidence sits behind it. The picture above rests on one phase-2 trial: roughly 338 participants, followed for 48 weeks. That is a small, relatively short, dose-finding study — the stage whose job is to explore doses and flag signals, not to settle a long-term safety profile.

• No long-term human safety data exists. Forty-eight weeks says nothing about effects over several years, and there is no large, completed long-term safety programme in the public record to fill that gap.
• The numbers are preliminary. Percentages from a few dozen people per dose arm can shift substantially in larger studies; they are early estimates, not stable rates.
• It is investigational and not an approved medicine. There is no manufacturer safety label of the kind that documents semaglutide and tirzepatide, so there is no equivalent authoritative summary of contraindications and warnings to draw on.

By contrast, tirzepatide and semaglutide are backed by large phase-3 programmes and years of real-world use, with detailed adverse-event tables and formal warnings. Retatrutide is not there yet — so every figure on this page is earliest-stage evidence, not a mature safety record.

Why the effects clustered during escalation

The phase-2 trial did not start participants at the top dose. It raised the dose stepwise over the opening weeks, and the gastrointestinal events tracked those steps — appearing as the dose was increased, then tending to settle. A lower 2 mg start also produced fewer events than a 4 mg start. This is why slow escalation is the central risk-reduction convention in the research literature: not a personal protocol, but the observation that faster or higher jumps produced more nausea, vomiting and diarrhoea. The escalation logic is set out, for research context only, in the retatrutide dosage guide.

Broader risk-reduction observations for the incretin class — smaller, slower meals, avoiding large or fatty meals during initiation, and keeping fluids up — come from the wider literature, not this trial. For vial formats, accurate reconstitution also matters, since an over-concentrated draw is effectively a larger dose; our peptide reconstitution calculator works out the water volume and draw for a target concentration.

When to seek medical help

Because retatrutide is investigational and its rarer effects are not well mapped, the threshold for professional assessment should be low. Signs that warrant stopping and getting proper medical review — not self-management — include:

• Severe or persistent abdominal pain, especially if it radiates to the back or comes with repeated vomiting.
• Vomiting or diarrhoea severe enough to prevent keeping fluids down, or a marked drop in how much urine you pass, which can signal dehydration.
• A rapid, pounding or persistently raised heartbeat, chest discomfort, or breathlessness, given the heart-rate rise observed in the trial.
• Swelling of the face, lips, tongue or throat, or difficulty breathing, which can indicate a serious allergic reaction.
• Upper-right abdominal pain, fever, or yellowing of the skin or eyes, which can point to gallbladder problems recognised across the incretin class.

This list errs deliberately toward caution and is not a substitute for a qualified clinician's judgement.

Research-use disclaimer

Retatrutide is supplied by BeSkinny strictly for laboratory and research purposes. It is an investigational compound and not an approved medicine, and nothing on this page is medical advice, a treatment recommendation or a human dosing protocol. Every figure describes what a single early-stage phase-2 trial reported, cited by standard research-reference convention; the evidence base is small, short and preliminary. Anyone experiencing symptoms should consult a registered healthcare professional, and individual suitability, interactions and dosing cannot be judged from a web page. For the broader safety framework across compounds, see are peptides safe?

Frequently asked questions

What are the most common retatrutide side effects?

In the phase-2 trial the most common were gastrointestinal: nausea, diarrhoea, vomiting, constipation and decreased appetite. Nausea led and was strongly dose-related, ranging from roughly 14% at the lowest dose to around 60% at the highest. Most events were mild to moderate and appeared mainly while the dose was being increased.

Are retatrutide side effects worse at higher doses?

Yes, in the trial they were clearly dose-related. Gastrointestinal events, the overall adverse-event rate, discontinuations and the heart-rate rise all rose at the higher 8 mg and 12 mg doses, and a lower 2 mg start produced fewer gastrointestinal events than a 4 mg start — which is why slow escalation is the convention in the literature.

How strong is the safety evidence for retatrutide?

It is early and limited. The side-effect data come from one phase-2 trial of about 338 people over 48 weeks — a dose-finding stage, not a long-term safety study. With no long-term human safety data and no manufacturer safety label, the profile is far less characterised than semaglutide's or tirzepatide's, and every figure should be read as preliminary.

Does retatrutide affect heart rate?

The phase-2 trial reported a dose-dependent increase in resting heart rate that rose through about 24 weeks and then declined over the following weeks. This was one of the main physiological signals watched in the study. What it means over the long term is not established, which is one reason the evidence base is described as early.

How does the side-effect profile compare with tirzepatide?

Both are gastrointestinal-predominant because they share the GLP-1 pathway, and both list nausea, diarrhoea, vomiting and constipation as the leading events. The key difference is evidence, not just mechanism: tirzepatide's profile comes from a large phase-3 programme, while retatrutide's comes from a single phase-2 trial. For a fuller comparison, see retatrutide vs tirzepatide. To review the compound and stocked strengths, see the retatrutide hub and the HD Labs Retatrutide 32 vial.

Sources

• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526. NEJM
• Jastreboff AM, et al. Retatrutide phase 2 obesity trial (adverse-event and safety data). PubMed record. PubMed
• Eli Lilly and Company. Lilly's phase 2 retatrutide results published in the New England Journal of Medicine (trial design and safety summary). Lilly investor release
• Drugs.com retatrutide monograph — notes that retatrutide is investigational, is not approved, has no established long-term safety, and lists the common gastrointestinal effects. There is no approved manufacturer product label for retatrutide. Drugs.com